NAA16: A Potential Drug Target and Biomarker (G79612)

Target Name: NAA16

NCBI ID: G79612

NAA16

NAA16: A Potential Drug Target and Biomarker

Nucleotide-associated adaptor proteins (NAPs) are a family of proteins that play a crucial role in the regulation of DNA binding and chromatin structure. One of the well-known NAPs is NAA16 (NARG1L), which is a protein that is expressed in various tissues and cell types. NAA16 has been shown to be involved in various cellular processes, including DNA replication, repair, and metabolism.

The search for new drug targets and biomarkers has become an essential part of modern medicine. Drug resistance is a major challenge in the treatment of disease, and the development of new drugs that can effectively treat a disease can be an effective way to improve treatment outcomes. NAA16 is a potential drug target and biomarker that has been identified, and its properties make it an attractive candidate for further investigation.

NAA16: Structure and Function

NAA16 is a 21 kDa protein that is composed of 215 amino acid residues. It has a nucleotide-binding domain (NBD) that is responsible for its DNA-binding properties. The NBD contains a nucleotide-binding domain that is composed of three parallel beta-helices, which are responsible for the formation of a stable nucleotide-protein complex.

NAA16 has been shown to play a role in the regulation of DNA replication and repair. It has been shown to interact with the protein p53, which is a well-known tumor suppressor protein. NAA16 has also been shown to play a role in the regulation of metabolism, including the regulation of cellular energy metabolism.

NAA16 has also been shown to be involved in the regulation of cellular signaling pathways. It has been shown to interact with various signaling proteins, including TGF-β1, which is a well-known growth factor protein. TGF-β1 has been shown to play a role in the regulation of cellular processes such as cell growth, differentiation, and inflammation.

Drug Targeting

NAA16 is a potential drug target due to its various functions in the regulation of cellular processes. One of the potential strategies for targeting NAA16 is to use small molecules that can interact with its various domains. NAA16 has been shown to be sensitive to inhibitors of the DNA-binding domain, as well as inhibitors of the NBD.

Another potential strategy for targeting NAA16 is to use antibodies that can recognize and selectively bind to it. This approach can be used to identify and target NAA16-expressing cells, including cancer cells.

Biomarker

NAA16 can also be used as a biomarker for various diseases, including cancer. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that NAA16 may be a useful biomarker for the diagnosis and prognosis of cancer.

Conclusion

NAA16 is a protein that has been shown to play a role in various cellular processes, including DNA replication, repair, and metabolism. Its potential as a drug target and biomarker makes it an attractive candidate for further investigation. The use of small molecules and antibodies to target NAA16 may be an effective way to treat various diseases, including cancer. Further studies are needed to fully understand the properties and functions of NAA16, and to develop effective strategies for its use as a drug target and biomarker.

Protein Name: N-alpha-acetyltransferase 16, NatA Auxiliary Subunit

Functions: Auxillary subunit of the N-terminal acetyltransferase A (NatA) complex which displays alpha (N-terminal) acetyltransferase activity

The "NAA16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAA16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets